Brian G. Priestly
- Oncology top 10%
- Pharmacology top 1%
- Health, Toxicology and Mutagenesis top 5%
- Molecular Biology
- Epidemiology
- Co-authors
- Gàbriel L. PlaaNeill H. StaceyRoger DrewJohn W. EdwardsMichel G. CôtéAndrew W. HarmanMalcolm SimAndrew J. Harford
- Topics
- Drug Transport and Resistance Mechanisms (13 papers)Carcinogens and Genotoxicity Assessment (8 papers)Drug-Induced Hepatotoxicity and Protection (8 papers)
In The Last Decade
Brian G. Priestly
44 papers receiving 844 citations
Peers
Comparison fields: 5 of 110
- Oncology 329
- Pharmacology 318
- Health, Toxicology and Mutagenesis 148
- Molecular Biology 121
- Epidemiology 112
Countries citing papers authored by Brian G. Priestly
This map shows the geographic impact of Brian G. Priestly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian G. Priestly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian G. Priestly more than expected).
Fields of papers citing papers by Brian G. Priestly
This network shows the impact of papers produced by Brian G. Priestly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian G. Priestly. The network helps show where Brian G. Priestly may publish in the future.
Co-authorship network of co-authors of Brian G. Priestly
This figure shows the co-authorship network connecting the top 25 collaborators of Brian G. Priestly. A scholar is included among the top collaborators of Brian G. Priestly based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian G. Priestly. Brian G. Priestly is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 28 | |
| 2 | 13 | |
| 3 | 46 | |
| 4 | Scientific Program: Selected Presentations - Cancer Clusters In the News: Risk Perception, Risk Communication and the Media | 0 |
| 5 | Current OHS best practices for the Australian nanotechnology industry: A position paper by the NanoSafe Australia Network | 8 |
| 6 | 3 | |
| 7 | Affective Evaluation, Trust, Perceived Risk and Acceptability of New Technology - the Case of Nanotechnology in Australia | 4 |
| 8 | 12 | |
| 9 | 5 | |
| 10 | 8 | |
| 11 | 5 | |
| 12 | 27 | |
| 13 | 26 | |
| 14 | 3 | |
| 15 | 8 | |
| 16 | 5 | |
| 17 | 6 | |
| 18 | 13 | |
| 19 | 1 | |
| 20 | 22 |
About Brian G. Priestly
Brian G. Priestly is a scholar working on Chemical Health and Safety, Pharmacology and Clinical Biochemistry, having authored 46 papers that have together received 884 indexed citations. Recurring topics across this work include Drug Transport and Resistance Mechanisms (13 papers), Carcinogens and Genotoxicity Assessment (8 papers) and Drug-Induced Hepatotoxicity and Protection (8 papers). The work is most often cited by research in Pharmacology (318 citations), Hepatology (100 citations) and Chemical Health and Safety (8 citations). Brian G. Priestly has collaborated with scholars based in Australia, Canada and Sweden. Frequent co-authors include Gàbriel L. Plaa, Neill H. Stacey, Roger Drew, John W. Edwards, Michel G. Côté, Andrew W. Harman, Malcolm Sim, Andrew J. Harford, D. B. Frewin and Ian R. Falconer. Their work appears in journals such as Pharmacological Reviews, Annals of the New York Academy of Sciences and Journal of Pharmacology and Experimental Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.